Research Article
Clinicopathological Features and Prognostic Implication of Gastric Carcinoma with Lymphoid Stroma
Table 1
Main characteristics of the eligible studies.
| | Location | Patient’s group | Number of patients | EBV positive rate | | Location | Patient’s group | Number of patients | EBV positive rate |
| Chang 2000 | Korea | GCLS w/EBV+ | 30 | 66.7% | Lopes 2004 | Brazil | GCLS | 7 | 57.1% | GCLS w/EBV- | 15 | Lu 2004 | China | GCLS | 17 |
| Chang 2001 | Korea | GCLS | 14 | 50.0% | | | Non-GCLS | 64 | | Non-GCLS | 292 | 3.4% | Min 2016 | Korea | GCLS | 145 | 85.5% |
| Cheng 2015 | China | GCLS w/EBV+ | 8 | | Mohri 2017 | Japan | GCLS | 15 | 66.7% | Non-GCLS w/EBV + | 45 | Ohtani 2009 | Japan | GCLS | 24 | 91.7% |
| Cho 2003 | Korea | GCLS | 9 | 77.8% | | | Non-GCLS | 35 | 5.7% | Non-GCLS | 21 | 19.0% | Osumi 2019 | Japan | GCLS | 80 | 75.0% |
| Cho 2004 | Korea | GCLS | 24 | 79.2% | Otsuji 2004 | Japan | GCLS | 31 | | Non-GCLS | 23 | 8.7% | | | Non-GCLS w/PD | 136 | |
| Gonzalez 2017 | USA | GCLS | 13 | | | | Non-GCLS w/WD | 799 | |
| Hirai 2016 | Japan | GCLS | 23 | | Park 2015 | Korea | GCLS | 46 | 80.4% |
| Hissong 2018 | USA | GCLS | 31 | 22.6% | | | Non-GCLS | 4236 | 6.5% |
| Huang 2013 | Taiwan | GCLS in EGC | 31 | | Ramos 2017 | Brazil | GCLS | 7 | | Non-GCLS in EGC | 520 | | | Non-GCLS | 248 | | GCLS in AGC | 191 | Ribeiro 2017 | Portugal | GCLS | 3 | 100.0% | Non-GCLS in AGC | 1217 | Selves 1996 | France | GCLS | 6 | 66.7% |
| Huang 2014 | Taiwan | GCLS w/EBV+ | 18 | | Setia 2019 | USA | GCLS | 17 | 64.7% | Non-GCLS w/EBV + | 33 | Shin 2017 | Korea | GCLS | 70 | |
| Huh 2016 | Korea | GCLS | 41 | 72.2% | | | Non-GCLS | 1626 | | Non-GCLS | 3344 | | Song 2010 | USA | GCLS w/EBV+ | 53 |
| Jing 1997 | Japan | GCLS | 8 | 37.5% | | | Non-GCLS w/EBV + | 18 | |
| Kang 2016 | Korea | GCLS | 60 | | Tobo 2013 | Japan | GCLS | 104 | 75.0% | Non-GCLS | 60 | | | Non-GCLS | 29 | 0.0% |
| Lim 2015 | Korea | GCLS | 274 | 86.1% | Wu 2000 | Taiwan | GCLS w/EBV+ | 11 | | Non-GCLS | 822 | | | | Non-GCLS w/EBV + | 19 |
| Lim 2017 | Korea | GCLS | 241 | 89.2% | | | Non-GCLS w/EBV- | 120 | | Non-GCLS | 1219 | | Yanagi 2019 | Japan | GCLS | 43 | 60.5% |
| Lim 2018 | Korea | GCLS | 40 | 90.0% | Yuen 1994 | Hong Kong | GCLS | 7 | 28.6% |
|
|
In gastric carcinoma with lymphoid stroma; EBV, Epstein-Barr virus; GCLS, gastric carcinoma with lymphoid stroma; w/, with; EGC, early gastric carcinoma; AGC, advanced gastric carcinoma; PD, poorly differentiated; WD, well differentiated. |